Navigation Links
Phase 1 Studies Show Promise of QuatRx's Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels
Date:1/29/2008

ns beyond statins.

About QuatRx

QuatRx Pharmaceuticals is focused on the discovery, licensing, development and commercialization of compounds in the endocrine, metabolic and cardiovascular therapeutic areas. In addition to sobetirome, QuatRx has three other product candidates in active clinical development and two preclinical development programs. Ophena(TM) which recently met all co-primary endpoints in a large, pivotal Phase 3 clinical trial, is a potential estrogen-free therapy for post-menopausal vaginal syndrome, a common problem that results from thinning of vaginal tissues associated with estrogen deficiency of menopause. Fispemifene is a new, selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for testosterone deficiency and associated disorders in men. Becocalcidiol, a patented Vitamin D analogue, is in Phase 2 clinical trials for the treatment of psoriasis through QuatRx's licensee, CollaGenex Pharmaceuticals, Inc. QuatRx's two preclinical small molecule programs are designed to address common endocrine disorders in women. For press release and other Company information, please visit http://www.quatrx.com.


'/>"/>
SOURCE QuatRx Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial
2. Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data
3. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
4. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
5. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
6. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
7. Transgenes Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer
8. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
9. Burrill Merchant Banking Advises NPS on Phase III Licensing Agreement
10. Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
11. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... 8 Amsterdam,Molecular Therapeutics (Euronext: AMT), a leader in ... part of the newly created Next Biotech Index of,NYSE ... our company,for this index," said Ronald Lorijn, CEO of ... companies and will help investors to track,the performance of ...
... team is proud to announce,the USDA/CVB has granted ... as well as an autogenous bacterin license utilizing ... approval of our manufacturing facility and our oral ... significant milestone for,our Company, and we look forward ...
... of Molecular Vision today,announces that discussions with Acrongenomics ... ceased. Acrongenomics has been unable to,complete on the ... of,Molecular Vision believes that the best interests of ... a conclusion. Acrongenomics remains a,significant shareholder in Molecular ...
Cached Biology Technology:Amsterdam Molecular Therapeutics Part of Next Biotech Index 2PerOs obtains USDA Establishment and Product Licenses for it's oral vaccine formulations 2
(Date:4/14/2014)... are continuing to unravel the molecular changes that underlie ... infections. , When the bacterium Yersinia pestis enters the ... 100 percent fatal if untreated. The way in which ... kills people in a matter of days has largely ... demonstrating that the presence of a protein called the ...
(Date:4/14/2014)... the decision of whether to get a dog. ... can be even more challenging. Now, a University ... in families of children with autism and found, ... reported the benefits of dog ownership included companionship, ... learn responsibility. , "Children with autism spectrum disorders ...
(Date:4/14/2014)... Think of the pressure change you feel when an elevator ... how you,d feel if that elevator carried you all the ... the blink of an eye. , That,s similar to what ... near a dam. For some, the change in pressure is ... seriously injured. , In an article in the March issue ...
Breaking Biology News(10 mins):Plague alters cell death to kill host 2Dog ownership benefits families of children with autism, MU researcher finds 2Making dams safer for fish around the world 2Making dams safer for fish around the world 3Making dams safer for fish around the world 4Making dams safer for fish around the world 5
... of Insect Molecular Biology reports the detailed analyses ... pest, the Pea Aphid. The analyses are based on ... and is a major step in enhancing our understanding of ... significant plant pests. The sequencing of the Pea ...
... have calculated the energy and economic potential of urban ... slurry for generating electricity in Spain. These residues are ... friendly and, in the case of solid urban waste, ... has economic and environmental advantages. "It gives added value ...
... the launch of the first Meteosat in 1977, 33 ... given meteorologists the tools to improve weather forecasting, with ... improving with data from operational satellites, like Meteosat Second ... basis for numerical forecasts, making use of the world,s ...
Cached Biology News:Successful genome sequencing of pea aphid is a breakthrough for ecology and agricultural research 2Successful genome sequencing of pea aphid is a breakthrough for ecology and agricultural research 3Waste could generate up to 7 percent of electricity in Spain 2Waste could generate up to 7 percent of electricity in Spain 3
...
...
... designed to rapidly and reliably amplify ... patented APA Technology. APAgene provides hassle-free, ... competitive price. All necessary ingredients are ... Kit can be used for identifying ...
Protein YIPF6 (YIP1 family member 6). [Source:Uniprot/SWISSPROT;Acc:Q96EC8] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: